阵发性睡眠性血红蛋白尿症 中国就医指南

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired, life-threatening hematologic disorder characterized by chronic intravascular hemolysis, bone marrow failure, and a markedly increased risk of thrombosis. It arises from a somatic mutation in the PIGA gene within a hematopoietic stem cell, leading to deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins—including CD55 and CD59—on the surface of blood cells. Without these regulatory proteins, red blood cells become hypersensitive to complement-mediated lysis, resulting in recurrent hemoglobinuria (often most noticeable in morning urine), fatigue, dyspnea, abdominal and esophageal pain, erectile dysfunction, and debilitating anemia. Thrombosis—particularly in atypical sites such as hepatic, portal, mesenteric, or cerebral veins—is the leading cause of mortality in PNH. Epidemiologically, PNH affects approximately 1–2 per million people globally, with an estimated prevalence of 5–10 per million in adults. It typically presents in adulthood (median age at diagnosis: 30–40 years), with no significant gender predilection. While the exact etiology remains unknown, PNH frequently evolves from underlying bone marrow failure syndromes—most commonly aplastic anemia—and may coexist with myelodysplastic syndromes. Risk factors include prior immune-mediated bone marrow injury, HLA-DR15 positivity, and clonal expansion of PIGA-mutated stem cells under immune selective pressure. Quality of life is profoundly impacted: patients report persistent fatigue, chronic pain, anxiety related to unpredictable hemolytic crises and thrombotic events, limitations in physical activity and employment, and psychosocial burden stemming from diagnostic delays (average time to diagnosis exceeds 1 year) and lifelong treatment dependency. Untreated, median survival is ~10 years; however, with modern complement inhibition therapy, 5-year survival now exceeds 90%. Despite therapeutic advances, many patients experience breakthrough hemolysis, residual cytopenias, renal impairment due to chronic hemoglobinuria, and long-term complications including pulmonary hypertension and iron deficiency anemia. Comprehensive care requires multidisciplinary coordination among hematologists, transfusion medicine specialists, nephrologists, and thrombosis experts.

# 阵发性睡眠性血红蛋白尿症（PNH）治疗方案与费用明细（血液科）

一、非手术/药物治疗方案

• •一线靶向治疗（C5抑制剂）：适用于经典型PNH伴溶血或血栓高风险者

- 替拉珠单抗（皮下注射）：年费用约55–65万元（含每月随访、补体活性检测、溶血指标复查）

• •支持治疗：铁剂、叶酸、输血（仅限严重贫血Hb＜70 g/L）、抗凝（如华法林，年均药检费约1200–2000元）

二、根治性治疗方案

• •异基因造血干细胞移植（allo-HSCT）：适用于年轻（＜50岁）、高危（反复血栓/骨髓衰竭转化）、无合适供者者优先考虑脐带血或HLA相合同胞供者

- 术前检查（骨髓形态+染色体+FISH+PNH克隆定量+HLA分型+病毒筛查等）：8000–12,000元

三、特殊/晚期方案

• •复发/耐药PNH（C5抑制剂失效）：换用新型C3抑制剂（如pegcetacoplan，国内临床试验阶段，暂未上市定价）；或联合小剂量阿扎胞苷（年费用约6–8万元，含骨髓监测）
• •合并骨髓增生异常综合征（MDS-PNH）：按MDS分层治疗，费用上浮20%–40%

方案快速选择指南

• •预算充足+中重度溶血：首选替拉珠单抗（性价比最优）
• •年轻高危+可获供者：推荐allo-HSCT（唯一根治手段）
• •老年/合并症多/轻症：依库珠单抗维持+支持治疗
• •经济受限：规范输血+铁剂+叶酸+定期监测（年均约3000–5000元）